Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 25 versus AMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 25 versus AMPHETAMINE SULFATE.
ADDERALL XR 25 vs AMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
None Documented
None Documented
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Category C
Category D/X
CNS Stimulant
CNS Stimulant